BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27907860)

  • 1. Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer.
    Heger Z; Polanska H; Krizkova S; Balvan J; Raudenska M; Dostalova S; Moulick A; Masarik M; Adam V
    Colloids Surf B Biointerfaces; 2017 Feb; 150():131-140. PubMed ID: 27907860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
    Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
    Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
    Zangemeister-Wittke U; Schenker T; Luedke GH; Stahel RA
    Br J Cancer; 1998 Oct; 78(8):1035-42. PubMed ID: 9792147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
    Song L; Coppola D; Livingston S; Cress D; Haura EB
    Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro.
    Khodadadian M; Leroux ME; Auzenne E; Ghosh SC; Farquhar D; Evans R; Spohn W; Zou Y; Klostergaard J
    Lung Cancer; 2009 Oct; 66(1):48-57. PubMed ID: 19195736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo.
    Jiang H; Zhao PJ; Su D; Feng J; Ma SL
    Mol Med Rep; 2014 Jun; 9(6):2265-72. PubMed ID: 24718383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.
    Santos A; Sarmento-Ribeiro AB; de Lima MC; Simões S; Moreira JN
    Cytometry A; 2008 Dec; 73A(12):1165-72. PubMed ID: 18785266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer" [Colloids Surf. B Biointerfaces 150 (2017) 131-140].
    Heger Z; Polanska H; Krizkova S; Balvan J; Raudenska M; Dostalova S; Moulick A; Masarik M; Adam V
    Colloids Surf B Biointerfaces; 2022 Apr; 212():112361. PubMed ID: 35131713
    [No Abstract]   [Full Text] [Related]  

  • 13. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax.
    Sirzén F; Zhivotovsky B; Nilsson A; Bergh J; Lewensohn R
    Lung Cancer; 1998 Oct; 22(1):1-13. PubMed ID: 9869102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEG-coumarin nanoaggregates as π-π stacking derived small molecule lipophile containing self-assemblies for anti-tumour drug delivery.
    Behl G; Kumar P; Sikka M; Fitzhenry L; Chhikara A
    J Biomater Sci Polym Ed; 2018 Mar; 29(4):360-375. PubMed ID: 29271302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB protein status and chemosensitivity in non-small cell lung cancers.
    Yamamoto Y; Shimizu E; Masuda N; Takada M; Sone S
    Oncol Rep; 1998; 5(2):447-51. PubMed ID: 9468577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation.
    Mathiyalagan R; Wang C; Kim YJ; Castro-Aceituno V; Ahn S; Subramaniyam S; Simu SY; Jiménez-Pérez ZE; Yang DC; Jung SK
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.